TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01486927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Description: In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa
Description: In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
Study: NCT04075721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3258
Description: Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3258
Description: Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3258 20 mg
Description: Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
Study: NCT01910259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Comparison with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Comparison with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Comparison with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03175900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoan dripping pills
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)
Study: NCT01761084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and behaviour change strategies
Description: 1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day.
Study: NCT02106052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching and toning exercise
Description: The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
Study: NCT00940589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Prolonged Release melatonin (Circadin) 2mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets, with identical features to the Circadin tablets
Study: NCT02636582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelipepimut-S Plus GM-CSF Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Given ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT00426244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment
Description: OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Ultrasound
Description: In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects.
Study: NCT01801228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study: NCT02636582

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT02291120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Study: NCT01801228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study: NCT00751400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: Consumer use of Extended Release Naproxen Sodium
Study: NCT04520646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: empagliflozin of 10mg/day is added on the basis of primary care
Study: NCT03967613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional eletrical stimulation
Description: Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
Study: NCT01930136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction (25%)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad libitum health diet
Study: NCT04185090

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID1803
Description: Amlodipine 10mg/Valsartan 160mg
Study: NCT01900717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
Study: NCT02199210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prompting forethought
Description: Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
Study: NCT04133129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Volume-High Intensity Interval Training
Description: On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
Study: NCT01782248

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnary and IRM

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnary and IRM
Study: NCT04185090

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID1801
Description: Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
Study: NCT01782248

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnary and IRM
Study: NCT01454141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Three sessions of CCT.
Study: NCT04185090

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ID1803+ID1801
Description: Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
Study: NCT00631774

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna SR
Description: Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna SR
Description: Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
Study: NCT04670185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIP SAMBA
Description: Behavioral parent management training
Study: NCT03413280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Description: Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
Study: NCT02830100

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Magnetic Resonance Imaging during intern speech, listening, talking, thinking.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT01222546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH5132799
Study: NCT03162770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
Study: NCT03298581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate
Description: Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
Study: NCT01454141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Vision Task
Description: Three sessions of PVT.
Study: NCT01923272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore Device
Description: Active stimulation to the vagal nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore Device
Description: Active stimulation to the vagal nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore
Description: Active AlphaCore treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore
Description: Active AlphaCore treatment
Study: NCT02415036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delcath Hepatic Delivery System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delcath Hepatic Delivery System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT00568165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile team
Description: a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study: NCT04159311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathy
Description: testing osteopathy Vs Treating osteopathy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathy
Description: testing osteopathy Vs Treating osteopathy
Study: NCT00908843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hydration with bicarbonate
Description: Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hydration with Sodium solution
Description: Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
Study: NCT03383341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cricket Protein Powder
Description: Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
Study: NCT03736772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3090106
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01171560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
Study: NCT01713023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The same described in Arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The same described in Arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: The same described in Arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: The same described in Arm description
Study: NCT02891655

Intervention type: OTHER
Intervention: immuno-histo-chemical analysis
Description: in vitro immuno-histo-chemical analysis of corneal epithelium
Study: NCT01140451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
Study: NCT00434252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
Study: NCT03629457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Mindful Self-Compassion
Description: Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Mindful Self-Compassion
Description: Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
Study: NCT04165707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keyto device + app
Description: Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers app
Description: The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
Study: NCT04423809

Intervention type: OTHER
Intervention: clinical assessment
Description: assessment of caregivers suffering when a family member is hospitalized
Study: NCT01143753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5212054
Description: Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5212054
Description: Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
Study: NCT04091529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADIOFREQUENCY ABLATION OF UTERINE MYOMAS
Description: The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
Study: NCT00434252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study: NCT01041755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Description: a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
Study: NCT01981590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.
Description: Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
Study: NCT00434252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered by IV infusion on the first day of each 3-week cycle
Study: NCT04683250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0953/HM06
Description: Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0953/HM06
Description: Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
Study: NCT03500432

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia of trnasperineal prostate biopsy
Description: three different block site with lidocaine
Study: NCT01041755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactose
Description: a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
Study: NCT03500432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia of trnasperineal prostate biopsy
Description: three different block site with lidocaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia of trnasperineal prostate biopsy
Description: three different block site with lidocaine